About: http://data.cimple.eu/news-article/adfcca555ef4a54c43a5a3cfd240c34dad551b5a80d775bb1461fbb9     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • Germany's CureVac announced Wednesday that final trial results showed its coronavirus vaccine had an efficacy rate of just 48 percent, far lower than those developed by mRNA rivals BioNTech and Moderna. The poor outcome had been expected after disappointing interim results were released earlier this month. CureVac said its vaccine did slightly better among people aged 18 to 60 than among older age groups, with efficacy climbing to 53 percent. The company said its trial was complicated by the prevalence of numerous coronavirus variants. mfp/jj
schema:headline
  • Covid vaccine from Germany's CureVac just 48% effective: final results
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...tology#hasEmotion
Faceted Search & Find service v1.16.123 as of May 22 2025


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3241 as of May 22 2025, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 10 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2026 OpenLink Software